News

Currently the president of McKesson Medical-Surgical, a unit of McKesson Corp, Tyler will succeed John Figueroa, who has accepted the position of CEO of Omnicare. Tyler will report

Initially, the joint venture will focus on commercialising buccally delivered insulin with an appropriate partner. Additionally, the companies have evaluated the safety of the nanoparticles in tolerability, acute

The studies will focus on the parkinson’s-implicated protein alpha-synuclein. Amicus chief scientific officer David Lockhart said that they are honored to receive this grant from the MJFF, which

Afatinib is an investigational orally administered irreversible inhibitor of both the epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2) tyrosine kinases. Boehringer Ingelheim said that

Healthpoint will ship commercial lots of Collagenase Santyl Ointment produced at DPT’s Lakewood facility to its North American customers, beginning this month. DPT’s Sterile & Specialty Products center

The product candidates cover a range of therapeutic areas, including pain, obesity and parkinson’s disease, using Angiochem’s technology to enable drugs to penetrate the CNS, including biologics (peptides

Elder Biomedia is a distributor and manufacturer of oral drugs in the Bulgarian pharma market. Elder Pharmaceuticals has recently increased its stake in Elder Biomedia from 61% to

Figueroa will replace James Shelton, who has served as Omnicare’s Interim president and CEO since August 2010. Most recently, Figueroa served as president of the US Pharmaceutical Group

Access Pharma anticipates completion and delivery of its CobOral insulin formulation to the pharmaceutical company by the end of the month. Access Pharma has recently signed an agreement